Evonik Q2 2026: Crosslinkers and Polymers Drive Best Quarter in Four Years
Evonik's Q2 2026 adjusted EBITDA surged 24% to €630 million as crosslinkers, high-performance polymers, and amino acids defied macro headwinds - a signal worth parsing for the process analytics sector.